Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nicardipine + nimustine
- Development stage
- Preclinical
- Lead developer
- Chugai Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of nicardipine, a dihydropyridine calcium channel blocker, and nimustine, a chemotherapeutic agent. This combination has shown promising results in the treatment of glioblastoma multiforme (GBM) at advanced stages. The therapy may work by combining nimustine's cytotoxic effects with nicardipine's ability to enhance drug delivery through vasodilation, potentially targeting cancer stem cells more effectively than standard treatments.
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)DNAEED (Embryonic ectoderm development protein)
Beyond the preview
Go deeper on nicardipine + nimustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nicardipine + nimustine.